Canagliflozin hemihydrate

Green-G

Brand Name(s):Invokana

Indication:Diabetes Mellitus -Type 2

Rationale:

Considered:Jan-14

Review Date:Feb-24

Comments:
Drug Safety Update
SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
Feb 2019
…………………………
NICE NG28 Update Type 2 diabetes in adults: management
May 2017
…………………………
Drug Safety Update
SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
Mar-17
…………………………
Drug Safety Update
signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
July 2016
…………………………
Drug Safety Update
Risk of diabetic ketoacidosis
April 2016
…………………………
Drug Safety Update
MHRA advises clinicians to test for raised ketones in patients on SGLT2 inhibitors.
Full guidance available at:https://www.gov.uk/drug-safety-update/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-risk-of-diabetic-ketoacidosis
June 2015
…………………………